Table of Contents
ISRN Cardiology
Volume 2012 (2012), Article ID 874706, 5 pages
http://dx.doi.org/10.5402/2012/874706
Clinical Study

The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease—A Retrospective Single Center Experience

1Department of Cardiology and Internal Medicine, St. John Hospital and Medical Center, Detroit, MI 48267-3271, USA
2Michigan Heart & Vascular Institute, Petoskey, MI, USA
3Sierra Nevada Cardiology Associates, Reno, NV, USA

Received 30 July 2012; Accepted 18 September 2012

Academic Editors: F. Boucher, D. Leung, and E. Liehn

Copyright © 2012 Andrzej Boguszewski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Diabetes Mellitus: a major risk factor for cardiovascular disease: a joint editorial statement by the American Diabetic Association, The National Heart, Lung, and Blood Institute, The Juvenile Diabetes Foundation International: The National Institute of Diabetes and Digestive and Kidney Disease: and The American Heart Association,” Circulation, vol. 100, pp. 1132–1133, 1999.
  2. N. A. Roper, R. W. Bilous, W. F. Kelly, N. C. Unwin, and V. M. Connolly, “Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study,” British Medical Journal, vol. 322, no. 7299, pp. 1389–1393, 2001. View at Google Scholar · View at Scopus
  3. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993. View at Google Scholar
  5. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp. S5–S20, 2003.
  8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Follow-up report on the diagnosis of diabetes mellitus,” Diabetes Care, vol. 26, no. 11, pp. 3160–3167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. “National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
  11. R. W. Nesto, “Correlation between cardiovascular disease and diabetes mellitus: current concepts,” American Journal of Medicine, vol. 116, supplement 5, pp. S11–S22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. W. A. Hsueh, C. J. Lyon, and M. J. Quiñones, “Insulin resistance and the endothelium,” American Journal of Medicine, vol. 117, no. 2, pp. 109–117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. V. Edelman, “The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors,” Reviews in Cardiovascular Medicine, vol. 4, no. 6, pp. S29–S37, 2003. View at Google Scholar · View at Scopus
  14. B. Balkau, M. Shipley, R. J. Jarrett et al., “High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study,” Diabetes Care, vol. 21, no. 3, pp. 360–367, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Sung, Y. M. Song, S. Ebrahim, and D. A. Lawlor, “Fasting blood glucose and the risk of stroke and myocardial infarction,” Circulation, vol. 119, no. 6, pp. 812–819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000. View at Google Scholar · View at Scopus
  17. R. B. Goldberg, D. M. Kendall, M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. D. S. Fredrickson, “An international classification of hyperlipidemias and hyperlipoproteinemias,” Annals of Internal Medicine, vol. 75, no. 3, pp. 471–472, 1971. View at Google Scholar · View at Scopus
  19. S. C. Port, M. O. Goodarzi, N. G. Boyle, and R. I. Jennrich, “Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease,” American Heart Journal, vol. 150, no. 2, pp. 209–214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. National Institute of Health (NIH), Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: The Evidence Report, Government Printing Office, Washington, DC, USA, 1998.
  21. E. Barrett-Connor, “Does hyperglycemia really cause coronary heart disease?” Diabetes Care, vol. 20, no. 10, pp. 1620–1623, 1997. View at Google Scholar · View at Scopus